How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/magnetic-resonance-angiography-mra-to-evaluate-adults-with-known-or-suspected-renal-occlusive-vascular-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected renal occlusive vascular disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected renal occlusive vascular disease (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected renal occlusive vascular disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
MultiHance 0.1 mmol/kg	MultiHance 0.1 mmol/kg	Bracco Diagnostics, Inc	Paramagnetic contrast agent; gadolinium-based MRI contrast medium	Water protons in tissue; blood-brain barrier; vascular endothelium

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Bracco Diagnostics, Inc · 1 drug in Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected renal occlusive vascular disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected renal occlusive vascular disease:

Cite this brief

Drug Landscape (2026). Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected renal occlusive vascular disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/magnetic-resonance-angiography-mra-to-evaluate-adults-with-known-or-suspected-renal-occlusive-vascular-disease. Accessed 2026-06-10.

Magnetic Resonance Angiography (MRA) to evaluate adults with known or suspected renal occlusive vascular disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing